Sangamo Therapeutics (SGMOQ) Retained Earnings (2010 - 2025)

Sangamo Therapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$1.5 million for Q4 2025.

• On a quarterly basis, Retained Earnings rose 99.9% year-over-year to -$1.5 million in Q4 2025; TTM through Dec 2025 was -$1.5 million, a 99.9% increase from a year earlier, with the FY2025 full-year figure at -$1.5 million, up 99.9% from the prior year.
• Retained Earnings rose to -$1.5 million in Q4 2025 per SGMOQ's latest filing, from -$1.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $2.0 million in Q2 2021 and bottomed at -$1.6 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$16.1 million (2022), against an average of -$609.3 million.
• Across the five-year window, Retained Earnings jumped 220.21% in 2021 and slumped 25177.27% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$956.3 million in 2021, then decreased by 20.11% to -$1.1 billion in 2022, then fell by 22.45% to -$1.4 billion in 2023, then decreased by 6.96% to -$1.5 billion in 2024, then surged by 99.9% to -$1.5 million in 2025.
• Per Business Quant, the three latest SGMOQ Retained Earnings figures stand at -$1.5 million (Q4 2025), -$1.6 billion (Q3 2025), and -$1.5 million (Q2 2025).